

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

IN RE COPAXONE 40 MG  
CONSOLIDATED CASES

C.A. No. 1:14-1171-GMS  
(CONSOLIDATED)

**STIPULATION AND [PROPOSED] ORDER  
CONCERNING CLAIM CONSTRUCTION DISPUTE**

Plaintiffs, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Teva Neuroscience, Inc. and Yeda Research and Development Co., Ltd. (collectively “Plaintiffs” or “Teva”) and Defendants Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively “Mylan”), Synthon Pharmaceuticals Inc., Synthon B.V., Synthon s.r.o. and Pfizer, Inc. (collectively “Synthon”), Sandoz Inc. and Momenta Pharmaceuticals, Inc. (“Sandoz”), Dr. Reddy’s Laboratories Ltd. (“DRL Ltd.”) and Dr. Reddy’s Laboratories, Inc. (“DRL Inc.”) (collectively, “DRL”); and Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals Company GmbH (collectively, “Amneal”) (collectively, “Defendants”) hereby stipulate and agree, subject to the approval of the Court, as follows:

1. Each of the following phrases constitutes a claim limitation, because the claimed invention is directed to patients already taking 20 mg glatiramer acetate daily by subcutaneous administration:

U.S. Patent 9,155,776 patent (the “776 patent”):

- “while inducing reduced severity of injection site reactions in the human patient relative to administration of 20 mg of glatiramer acetate

s.c. daily” and “with reduced severity of injection site reactions relative to administration of 20 mg of glatiramer acetate s.c. daily” (claim 1);

- “induces reduced frequency and severity of immediate post injection reactions and injection site reactions in the human patient relative to administration of 20 mg of glatiramer acetate s.c. daily” (claim 2);
- “with reduced severity of injection site reactions relative to administration of 20 mg of glatiramer acetate s.c. daily” (claim 5);
- “induces reduced frequency and severity of immediate post injection reactions and injection site reactions in the human patient relative to administration of 20 mg of glatiramer acetate s.c. daily” (claim 9);
- “with reduced severity of injection site reactions relative to administration of 20 mg of glatiramer acetate s.c. daily” (claim 12);
- “with reduced frequency and severity of immediate post injection reactions and injection site reactions relative to administration of 20 mg of glatiramer acetate s.c. daily” (claim 13);
- “with reduced severity of injection site reactions relative to administration of 20 mg of glatiramer acetate s.c. daily” (claim 16);
- “which treats the human patient with reduced frequency and severity of immediate post injection reactions and injection site reactions relative to administration of 20 mg of glatiramer acetate s.c. daily” (claims 21-24);

- “improving the tolerability of glatiramer acetate treatment” (claim 12);  
and
- “improving the tolerability of glatiramer acetate therapy” (claim 16);

U.S. Patent 8,232,250 (the “250 patent”)

- “wherein the frequency of an immediate post injection reaction or the frequency of an injection site reaction is reduced relative to daily subcutaneous administration of 20 mg glatiramer acetate” (claim 14);
- “increasing the tolerability of GA treatment” (claim 15);
- “so as to thereby increase the tolerability of GA treatment in the patient” (claim 15);
- “wherein increasing the tolerability of glatiramer acetate treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an immediate post injection reaction” (claim 16); and
- “wherein increasing the tolerability of glatiramer acetate treatment in the human patient suffering from a relapsing form of multiple sclerosis comprises reducing the frequency of an injection site reaction” (claim 17);

U.S. Patent 8,399,413 (the “413 patent”):

- “wherein the frequency of an immediate post injection reaction or the frequency of an injection site reaction is reduced relative to daily subcutaneous administration of 20 mg glatiramer acetate” (claim 7).

1. Regarding the '776 patent and the construction of the terms “reduced severity of injection site reactions” and “reduced frequency and severity of immediate post injection reactions and injection site reactions”:
  - “Frequency” means the rate of occurrence of a patient’s ISRs and/or IPIRs; and
  - “Severity” means the intensity of a patient’s ISRs and/or IPIRs.

**SO AGREED AND STIPULATED**

Date: February 10, 2016

BAYARD, P.A.

/s/ Stephen B. Brauerman

Richard D. Kirk (No. 922)  
Stephen B. Brauerman (No. 4952)  
Vanessa R. Tiradentes (No. 5398)  
Sara E. Bussiere (No. 5725)  
222 Delaware Avenue, Suite 900  
Wilmington, DE 19801  
(302) 655-5000  
rkirk@bayardlaw.com  
sbrauerman@bayardlaw.com  
vtiradentes@bayardlaw.com  
sbussiere@bayardlaw.com

David M. Hashmall  
Elizabeth J. Holland  
GOODWIN PROCTER LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018-1405  
(212) 813-8800

Daryl L. Wiesen  
John T. Bennett  
Nicholas K. Mitrokostas  
GOODWIN PROCTER LLP  
Exchange Place  
53 State Street  
Boston, MA 02109  
(617) 570-1000

William G. James  
GOODWIN PROCTER LLP  
901 New York Avenue, NW  
Washington, DC 20001  
(202) 346-4000

*Attorneys for Plaintiffs Teva  
Pharmaceuticals USA, Inc., Teva  
Pharmaceutical Industries, Ltd., Teva  
Neuroscience, Inc. and Yeda*

SHAW KELLER LLP

/s/ John W. Shaw

John W. Shaw (No. 3362)  
Karen E. Keller (No. 4489)  
300 Delaware Avenue, Suite 1120  
Wilmington, DE 19801  
(302) 298-0700  
jshaw@shawkeller.com  
kkeller@shawkeller.com

David M. Hashmall  
Elizabeth J. Holland  
GOODWIN PROCTER LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018-1405  
(212) 813-8800

Daryl L. Wiesen  
John T. Bennett  
Nicholas K. Mitrokostas  
GOODWIN PROCTER LLP  
Exchange Place  
53 State Street  
Boston, MA 02109  
(617) 570-1000

William G. James  
GOODWIN PROCTER LLP  
901 New York Avenue, NW  
Washington, DC 20001  
(202) 346-4000

*Attorneys for Plaintiffs Teva  
Pharmaceuticals USA, Inc., Teva  
Pharmaceutical Industries, Ltd., Teva  
Neuroscience, Inc. and Yeda*

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.